*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The securities are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated April 27, 2026 (the "**Prospectus**") issued by Cofoe Medical Technology Co., Ltd. (可孚醫療科技股份有限公司) (the "**Company**") for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.*

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

Potential investors of the Offer Shares should note that the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Wednesday, May 6, 2026).

Cofoe Medical Technology Co., Ltd.*
可孚醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1187)

ANNOUNCEMENT OF OFFER PRICE

We refer to the Prospectus issued by the Company on April 27, 2026.

On May 3, 2026, the Offer Price was determined at HK$39.33 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%).

The Company expects to announce details of the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering, the basis of allocations of the Hong Kong Offer Shares and the results of allocations in the Hong Kong Public Offering on Tuesday, May 5, 2026 in the manner described in the section headed "How to Apply for Hong Kong Offer Shares – B. Publication of Results" in the Prospectus.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, May 6, 2026 (Hong Kong time), dealings in the H Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, May 6, 2026 (Hong Kong time). The H Shares will be traded in board lots of 100 H Shares each. The stock code of the H Shares is 1187.

By order of the Board
Cofoe Medical Technology Co., Ltd.
Mr. ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, May 4, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. Zhou Rong as independent non-executive directors.

* *for identification purpose only*